CURE Pharmaceutical Takes First Step to Acquire Coeptis Pharmaceuticals and its Combination Drug for Osteoarthritis Pain and Hypertension

GlobeNewswire•November 14, 2019 OXNARD, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR) (“CURE”), an innovative drug delivery and development company, today announced that it purchased a $200,000 convertible promissory note issued by Coeptis Pharmaceuticals, Inc., a biopharmaceutical company engaged in the acquisition, development and commercialization of branded 505(b)(2) pharmaceutical products. This note represents…

Blog, Company News, News, twitter

CURE Pharmaceutical Debuts CUREform Drug Delivery Line Adding Chewables and Emulsions

GlobeNewswire•October 9, 2019 Alternative dosage demand drives company’s manufacturing expansion OXNARD, Calif., Oct. 09, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, announces the expansion of its oral drug delivery product line creating CUREform™ which includes CUREfilm®, one of the most advanced oral thin films on the market today.…

Blog, Company News, News, twitter

CURE Pharmaceutical Promotes Dr. Vered Gigi to Chief Scientific Officer

GlobeNewswire•October 1, 2019 Biopharma star brings extensive translational research experience as company advances its clinical indications OXNARD, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, has appointed Dr. Vered Gigi as its chief scientific officer. In this role, Dr. Gigi will oversee all CURE’s research and…

Blog, Company News, News, twitter

CURE Pharmaceutical Takes First Step To Secure Hemp CBD Supply Chain by Partnering with Fytiko Farms

GlobeNewswire•August 21, 2019 OXNARD, Calif., Aug. 21, 2019 (GLOBE NEWSWIRE) –– CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced it has signed a deal with Oklahoma-based hemp grower Fytiko Farms. The deal gives CURE direct, guaranteed access to high-quality plant material for exclusive use in its proprietary oral thin film (OTF)…

Blog, Company News, News, twitter

CURE Pharmaceutical – Our Q2 2019 Update

We start our third quarter having acquired enabling new technology that expands our oral drug delivery capabilities, along with a significant capital infusion. We are pleased to share our post-acquisition investor presentation below, integrating the technology acquired from Chemistry Holdings in our product pipeline. Our primary focus will be on the pharmaceutical and nutraceutical cannabinoid…

Company News, News

Cure Pharmaceutical Expands Board with Two Women Directors

GlobeNewswire•August 7, 2019 OXNARD, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the addition of two directors to its Board, Dr. Lauren Chung, Ph.D. and Mrs. Anya Goldin. Dr. Chung has experience in healthcare investments and academic accomplishments in scientific fields and Goldin brings…

Blog, Company News, News, twitter

Cure Pharmaceutical Secures Patent on High Loading of Active Ingredients in Oral Thin Film

GlobeNewswire•July 24, 2019 OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 13/890,875. The new patent builds on one of CURE’s key technology differentiators – loading higher amounts of drug active on an oral thin film (OTF) using…

Blog, Company News, News, twitter

CURE Pharmaceutical Secures Patent on Oral Thin Films With Bi-Phasic Release of Natural Ingredients

GlobeNewswire•July 16, 2019 OXNARD, Calif., July 16, 2019 (GLOBE NEWSWIRE) — CURE Pharmaceutical (CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No. 15/666,057, which covers edible thin films with natural active ingredients located in both a powder coating and the film matrix for a bi-phasic release profile. “With…

Blog, Company News, News, twitter

Energy Fuels Commends President Trump on his Decision to Reinvigorate the Nuclear Fuel Supply Chain and Looks Forward to Working with the Trump Administration to Support the U.S. Uranium Mining Industry; First Land Cleanup Contract Signed

PR Newswire•July 15, 2019 LAKEWOOD, CO, July 15, 2019 /PRNewswire/ – Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels” or the “Company”), the largest uranium producer in the U.S., is pleased to announce that our petition, filed jointly with Ur-Energy Inc. under Section 232 of the Trade Expansion Act of 1962, has been…

Blog, Company News, News, twitter

There Has Been No Announced Decision with Respect to the Uranium Section 232 Trade Action

PR NewswireJuly 12, 2019 DENVER, July 12, 2019 /PRNewswire/ — Ur-Energy Inc. (NYSE American: URG; TSX: URE) (“Ur-Energy”) and Energy Fuels Inc. (NYSE American: UUUU; TSX: EFR) (“Energy Fuels”) confirm that they are unaware of any decision by the White House with respect to the U.S. Department of Commerce (“DOC”) investigation into the effects of uranium…

Blog, Company News, News, twitter